 Craig Friesen
Concepts (397)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dyspepsia | 27 | 2024 | 51 | 9.000 |
Why?
| | Abdominal Pain | 30 | 2024 | 71 | 7.940 |
Why?
| | Gastrointestinal Diseases | 15 | 2023 | 46 | 5.050 |
Why?
| | Eosinophilia | 14 | 2024 | 27 | 4.700 |
Why?
| | Irritable Bowel Syndrome | 8 | 2023 | 17 | 3.940 |
Why?
| | Intestinal Mucosa | 12 | 2024 | 38 | 3.610 |
Why?
| | Adolescent | 63 | 2024 | 2183 | 3.550 |
Why?
| | Eosinophils | 17 | 2022 | 29 | 3.510 |
Why?
| | Child | 74 | 2024 | 3348 | 3.460 |
Why?
| | Mast Cells | 13 | 2022 | 22 | 3.300 |
Why?
| | Male | 69 | 2024 | 3367 | 3.160 |
Why?
| | Female | 69 | 2024 | 3534 | 3.100 |
Why?
| | Humans | 93 | 2024 | 6929 | 3.000 |
Why?
| | Sleep Wake Disorders | 5 | 2024 | 22 | 2.790 |
Why?
| | Depression | 7 | 2024 | 68 | 2.660 |
Why?
| | Anxiety | 6 | 2024 | 50 | 2.540 |
Why?
| | Food Hypersensitivity | 5 | 2023 | 17 | 2.320 |
Why?
| | Chronic Pain | 6 | 2024 | 31 | 2.020 |
Why?
| | Inflammatory Bowel Diseases | 5 | 2019 | 41 | 1.890 |
Why?
| | Gastric Mucosa | 6 | 2021 | 14 | 1.880 |
Why?
| | Retrospective Studies | 22 | 2024 | 1337 | 1.810 |
Why?
| | Duodenum | 8 | 2022 | 19 | 1.740 |
Why?
| | Inflammation | 7 | 2022 | 49 | 1.630 |
Why?
| | Urinary Bladder, Overactive | 2 | 2023 | 4 | 1.470 |
Why?
| | Gastric Emptying | 5 | 2019 | 9 | 1.450 |
Why?
| | Postprandial Period | 6 | 2024 | 16 | 1.400 |
Why?
| | Heart Rate | 4 | 2020 | 26 | 1.300 |
Why?
| | Gastritis | 5 | 2024 | 12 | 1.250 |
Why?
| | Antibodies, Monoclonal | 4 | 2013 | 23 | 1.210 |
Why?
| | Gastroenterology | 2 | 2022 | 10 | 1.170 |
Why?
| | Meals | 2 | 2024 | 15 | 1.130 |
Why?
| | Child, Preschool | 21 | 2024 | 1562 | 1.130 |
Why?
| | Carbohydrate Metabolism, Inborn Errors | 3 | 2021 | 3 | 1.110 |
Why?
| | Autonomic Nervous System | 3 | 2020 | 9 | 1.100 |
Why?
| | Esophagitis | 4 | 2020 | 7 | 1.040 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2015 | 15 | 1.040 |
Why?
| | Enterocolitis | 3 | 2015 | 36 | 0.990 |
Why?
| | Gastroesophageal Reflux | 6 | 2018 | 41 | 0.980 |
Why?
| | Nausea | 2 | 2024 | 16 | 0.960 |
Why?
| | Gastroparesis | 2 | 2019 | 4 | 0.930 |
Why?
| | Lactase | 2 | 2021 | 2 | 0.930 |
Why?
| | Biopsy | 9 | 2022 | 63 | 0.920 |
Why?
| | Urination Disorders | 1 | 2023 | 4 | 0.910 |
Why?
| | Urinary Bladder Diseases | 1 | 2023 | 3 | 0.910 |
Why?
| | Surveys and Questionnaires | 10 | 2022 | 275 | 0.910 |
Why?
| | Colon | 2 | 2021 | 12 | 0.910 |
Why?
| | Tick Bites | 1 | 2023 | 1 | 0.910 |
Why?
| | Th17 Cells | 2 | 2020 | 5 | 0.900 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2013 | 33 | 0.900 |
Why?
| | Anaphylaxis | 1 | 2023 | 10 | 0.890 |
Why?
| | Cross-Sectional Studies | 7 | 2023 | 333 | 0.880 |
Why?
| | Cell Count | 7 | 2022 | 16 | 0.850 |
Why?
| | Emergency Medical Services | 1 | 2022 | 15 | 0.820 |
Why?
| | Headache | 2 | 2020 | 14 | 0.820 |
Why?
| | Colonic Diseases | 1 | 2021 | 5 | 0.780 |
Why?
| | Heartburn | 1 | 2021 | 2 | 0.780 |
Why?
| | Acetates | 3 | 2009 | 5 | 0.760 |
Why?
| | Quinolines | 3 | 2009 | 6 | 0.760 |
Why?
| | Leukotriene Antagonists | 3 | 2009 | 6 | 0.760 |
Why?
| | Duodenitis | 3 | 2021 | 4 | 0.750 |
Why?
| | Psychophysiologic Disorders | 1 | 2020 | 3 | 0.730 |
Why?
| | Intestine, Large | 1 | 2020 | 1 | 0.730 |
Why?
| | Drinking | 3 | 2009 | 8 | 0.720 |
Why?
| | Pediatrics | 2 | 2014 | 183 | 0.710 |
Why?
| | Cold Temperature | 1 | 2019 | 3 | 0.700 |
Why?
| | Gastrointestinal Motility | 1 | 2019 | 5 | 0.700 |
Why?
| | Stress, Physiological | 1 | 2019 | 8 | 0.700 |
Why?
| | Capsule Endoscopy | 1 | 2019 | 4 | 0.690 |
Why?
| | Ileum | 1 | 2019 | 15 | 0.680 |
Why?
| | Gastrointestinal Tract | 1 | 2018 | 7 | 0.640 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 122 | 0.640 |
Why?
| | Eating | 2 | 2009 | 32 | 0.640 |
Why?
| | Tooth Erosion | 1 | 2017 | 1 | 0.610 |
Why?
| | Duodenal Diseases | 2 | 2010 | 4 | 0.600 |
Why?
| | Intestines | 2 | 2015 | 28 | 0.600 |
Why?
| | Endoscopy, Digestive System | 4 | 2022 | 8 | 0.590 |
Why?
| | Immunoglobulin E | 2 | 2023 | 22 | 0.590 |
Why?
| | Esophagus | 5 | 2017 | 28 | 0.580 |
Why?
| | Electromyography | 3 | 2020 | 7 | 0.540 |
Why?
| | Age Factors | 5 | 2021 | 211 | 0.530 |
Why?
| | Crohn Disease | 6 | 2024 | 25 | 0.530 |
Why?
| | Severity of Illness Index | 7 | 2019 | 148 | 0.520 |
Why?
| | Infant | 17 | 2022 | 1449 | 0.520 |
Why?
| | Treatment Outcome | 9 | 2024 | 649 | 0.510 |
Why?
| | Pyloric Antrum | 2 | 2020 | 4 | 0.500 |
Why?
| | Diarrhea | 4 | 2023 | 18 | 0.500 |
Why?
| | Stomach | 4 | 2015 | 11 | 0.480 |
Why?
| | Chronic Disease | 10 | 2020 | 106 | 0.480 |
Why?
| | Primary Health Care | 1 | 2014 | 41 | 0.480 |
Why?
| | Prospective Studies | 8 | 2019 | 547 | 0.470 |
Why?
| | Quality of Life | 3 | 2023 | 139 | 0.470 |
Why?
| | Somatoform Disorders | 2 | 2010 | 6 | 0.460 |
Why?
| | Practice Patterns, Physicians' | 2 | 2014 | 85 | 0.450 |
Why?
| | Electrocardiography | 3 | 2020 | 20 | 0.430 |
Why?
| | Relaxation Therapy | 3 | 2019 | 6 | 0.420 |
Why?
| | Pain Measurement | 5 | 2019 | 48 | 0.410 |
Why?
| | Avoidance Learning | 2 | 2022 | 6 | 0.410 |
Why?
| | Cromolyn Sodium | 2 | 2006 | 3 | 0.390 |
Why?
| | Emergency Service, Hospital | 3 | 2022 | 129 | 0.360 |
Why?
| | Biofeedback, Psychology | 1 | 2010 | 3 | 0.360 |
Why?
| | Risk Factors | 3 | 2021 | 490 | 0.360 |
Why?
| | Case-Control Studies | 5 | 2018 | 216 | 0.360 |
Why?
| | Myoelectric Complex, Migrating | 2 | 2006 | 4 | 0.360 |
Why?
| | Satiation | 2 | 2024 | 5 | 0.330 |
Why?
| | Acetaminophen | 2 | 2019 | 18 | 0.320 |
Why?
| | Electrophysiology | 1 | 2008 | 6 | 0.320 |
Why?
| | Self Report | 3 | 2021 | 41 | 0.310 |
Why?
| | Cross-Over Studies | 3 | 2024 | 35 | 0.310 |
Why?
| | Gastrointestinal Agents | 2 | 2004 | 4 | 0.310 |
Why?
| | Prevalence | 6 | 2018 | 150 | 0.300 |
Why?
| | Pilot Projects | 5 | 2024 | 114 | 0.290 |
Why?
| | Animals | 4 | 2023 | 741 | 0.280 |
Why?
| | United States | 3 | 2019 | 670 | 0.280 |
Why?
| | Histamine Antagonists | 1 | 2006 | 8 | 0.270 |
Why?
| | Sleep | 4 | 2020 | 37 | 0.270 |
Why?
| | Adult | 9 | 2021 | 1199 | 0.270 |
Why?
| | Cystic Fibrosis | 2 | 1995 | 20 | 0.250 |
Why?
| | Prognosis | 2 | 2021 | 216 | 0.250 |
Why?
| | Fear | 2 | 2022 | 17 | 0.250 |
Why?
| | Ketotifen | 1 | 2024 | 3 | 0.240 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 18 | 0.240 |
Why?
| | Cytokines | 2 | 2018 | 48 | 0.240 |
Why?
| | Radionuclide Imaging | 2 | 2019 | 6 | 0.240 |
Why?
| | Technetium Tc 99m Sulfur Colloid | 2 | 2019 | 4 | 0.240 |
Why?
| | Time Factors | 5 | 2019 | 263 | 0.240 |
Why?
| | Mammals | 1 | 2023 | 4 | 0.230 |
Why?
| | Constipation | 2 | 2021 | 15 | 0.220 |
Why?
| | Breath Tests | 2 | 2020 | 11 | 0.220 |
Why?
| | Brain | 1 | 2023 | 79 | 0.210 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2022 | 5 | 0.210 |
Why?
| | Postpartum Period | 2 | 1999 | 7 | 0.210 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2022 | 20 | 0.210 |
Why?
| | Lactation | 2 | 1999 | 5 | 0.210 |
Why?
| | Breast Feeding | 2 | 1999 | 24 | 0.210 |
Why?
| | Sensitivity and Specificity | 3 | 2019 | 151 | 0.210 |
Why?
| | Feeding and Eating Disorders | 1 | 2022 | 8 | 0.210 |
Why?
| | Models, Psychological | 1 | 2021 | 6 | 0.200 |
Why?
| | Disaccharidases | 1 | 2021 | 1 | 0.190 |
Why?
| | Colonoscopy | 1 | 2021 | 15 | 0.190 |
Why?
| | Infliximab | 3 | 2013 | 7 | 0.190 |
Why?
| | Sulfides | 3 | 2009 | 6 | 0.190 |
Why?
| | Cyclopropanes | 3 | 2009 | 7 | 0.190 |
Why?
| | Sucrase | 1 | 2020 | 1 | 0.190 |
Why?
| | Monitoring, Physiologic | 4 | 1994 | 23 | 0.180 |
Why?
| | Comorbidity | 2 | 2019 | 56 | 0.180 |
Why?
| | Follow-Up Studies | 3 | 2019 | 329 | 0.180 |
Why?
| | Helicobacter pylori | 1 | 2020 | 4 | 0.180 |
Why?
| | Helicobacter Infections | 1 | 2020 | 4 | 0.180 |
Why?
| | Affect | 1 | 2020 | 8 | 0.180 |
Why?
| | Biomarkers | 3 | 2024 | 132 | 0.180 |
Why?
| | Electromagnetic Phenomena | 1 | 2019 | 2 | 0.180 |
Why?
| | Cholecystitis | 1 | 2019 | 6 | 0.170 |
Why?
| | Pain Clinics | 1 | 2019 | 2 | 0.170 |
Why?
| | Patient Care Team | 1 | 2019 | 18 | 0.170 |
Why?
| | Radiopharmaceuticals | 1 | 2019 | 5 | 0.170 |
Why?
| | Genes, Regulator | 1 | 2019 | 4 | 0.170 |
Why?
| | Hepatocytes | 1 | 2019 | 8 | 0.170 |
Why?
| | Midwestern United States | 2 | 2016 | 35 | 0.170 |
Why?
| | Milk Hypersensitivity | 2 | 2015 | 3 | 0.170 |
Why?
| | Cost Savings | 1 | 2019 | 10 | 0.170 |
Why?
| | Gastroenteritis | 1 | 1999 | 26 | 0.170 |
Why?
| | Women, Working | 1 | 1999 | 1 | 0.170 |
Why?
| | Patient Compliance | 1 | 2019 | 56 | 0.170 |
Why?
| | CRISPR-Cas Systems | 1 | 2019 | 13 | 0.170 |
Why?
| | Inpatients | 1 | 2019 | 43 | 0.170 |
Why?
| | Social Support | 1 | 1999 | 26 | 0.160 |
Why?
| | Body Weight | 1 | 2018 | 52 | 0.160 |
Why?
| | Statistics as Topic | 1 | 2018 | 19 | 0.160 |
Why?
| | Proton Pump Inhibitors | 1 | 2018 | 17 | 0.160 |
Why?
| | Protective Agents | 1 | 2018 | 2 | 0.160 |
Why?
| | Mandibular Neoplasms | 1 | 2018 | 2 | 0.160 |
Why?
| | Osteosclerosis | 1 | 2018 | 2 | 0.160 |
Why?
| | Dentofacial Deformities | 1 | 2018 | 2 | 0.160 |
Why?
| | Osteoma | 1 | 2018 | 3 | 0.160 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 8 | 0.160 |
Why?
| | Adenomatous Polyposis Coli Protein | 1 | 2018 | 5 | 0.160 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2018 | 8 | 0.160 |
Why?
| | Pain Management | 1 | 2018 | 27 | 0.160 |
Why?
| | Cholelithiasis | 2 | 2006 | 7 | 0.160 |
Why?
| | Infant, Newborn | 7 | 2022 | 826 | 0.160 |
Why?
| | Combined Modality Therapy | 2 | 2010 | 47 | 0.160 |
Why?
| | Exercise | 1 | 2019 | 132 | 0.150 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2018 | 24 | 0.150 |
Why?
| | Oral Hygiene | 1 | 2017 | 2 | 0.150 |
Why?
| | Esophagoscopy | 1 | 2017 | 11 | 0.150 |
Why?
| | Referral and Consultation | 2 | 2019 | 32 | 0.150 |
Why?
| | Diet | 1 | 2017 | 54 | 0.150 |
Why?
| | Pain | 4 | 2022 | 56 | 0.140 |
Why?
| | Hydrogen-Ion Concentration | 5 | 1995 | 21 | 0.140 |
Why?
| | Receptors, Steroid | 1 | 2016 | 5 | 0.140 |
Why?
| | Analysis of Variance | 3 | 2012 | 25 | 0.140 |
Why?
| | Bilirubin | 2 | 2022 | 25 | 0.140 |
Why?
| | Intestine, Small | 1 | 2016 | 15 | 0.140 |
Why?
| | Milk Proteins | 1 | 2015 | 1 | 0.140 |
Why?
| | Immune Tolerance | 1 | 2015 | 8 | 0.140 |
Why?
| | Pediatric Obesity | 1 | 2018 | 130 | 0.130 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2015 | 1 | 0.130 |
Why?
| | Infant Formula | 1 | 2015 | 16 | 0.130 |
Why?
| | Electrodiagnosis | 2 | 2006 | 4 | 0.130 |
Why?
| | C-Reactive Protein | 1 | 1995 | 16 | 0.130 |
Why?
| | Psychology, Child | 2 | 2012 | 12 | 0.130 |
Why?
| | Ghrelin | 1 | 2015 | 6 | 0.130 |
Why?
| | Colitis | 1 | 2015 | 13 | 0.130 |
Why?
| | Hydrochloric Acid | 1 | 1994 | 1 | 0.120 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 1994 | 1 | 0.120 |
Why?
| | Apnea | 1 | 1994 | 5 | 0.120 |
Why?
| | Critical Illness | 1 | 1994 | 22 | 0.120 |
Why?
| | Allergens | 1 | 2015 | 58 | 0.120 |
Why?
| | Colitis, Ulcerative | 2 | 2024 | 13 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 2 | 2013 | 11 | 0.120 |
Why?
| | Health Care Surveys | 1 | 2014 | 33 | 0.120 |
Why?
| | Permeability | 1 | 2014 | 7 | 0.120 |
Why?
| | Double-Blind Method | 2 | 2024 | 45 | 0.120 |
Why?
| | Edema | 2 | 2015 | 7 | 0.120 |
Why?
| | Sick Role | 1 | 2013 | 2 | 0.110 |
Why?
| | Illness Behavior | 1 | 2013 | 2 | 0.110 |
Why?
| | Adalimumab | 1 | 2013 | 2 | 0.110 |
Why?
| | Remission Induction | 1 | 2013 | 24 | 0.110 |
Why?
| | Endoscopy | 1 | 2013 | 16 | 0.110 |
Why?
| | Asthma | 1 | 1995 | 152 | 0.110 |
Why?
| | Parenting | 1 | 2013 | 22 | 0.110 |
Why?
| | Parent-Child Relations | 1 | 2013 | 36 | 0.110 |
Why?
| | Interprofessional Relations | 1 | 2012 | 5 | 0.110 |
Why?
| | Affective Symptoms | 1 | 2012 | 3 | 0.110 |
Why?
| | Cooperative Behavior | 1 | 2012 | 24 | 0.110 |
Why?
| | Socioeconomic Factors | 2 | 2006 | 53 | 0.110 |
Why?
| | Gastric Fundus | 1 | 1992 | 3 | 0.110 |
Why?
| | Fecal Impaction | 1 | 2012 | 3 | 0.100 |
Why?
| | Laxatives | 1 | 2012 | 5 | 0.100 |
Why?
| | Cathartics | 1 | 2012 | 4 | 0.100 |
Why?
| | Emergencies | 1 | 2012 | 11 | 0.100 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 9 | 0.100 |
Why?
| | Enema | 1 | 2012 | 15 | 0.100 |
Why?
| | Sex Factors | 3 | 2007 | 68 | 0.090 |
Why?
| | Vomiting | 3 | 2020 | 23 | 0.090 |
Why?
| | Mucositis | 1 | 2010 | 3 | 0.090 |
Why?
| | Eosinophilic Esophagitis | 2 | 2024 | 6 | 0.090 |
Why?
| | Education, Graduate | 1 | 1990 | 1 | 0.090 |
Why?
| | Occupational Health Services | 1 | 1990 | 1 | 0.090 |
Why?
| | Nutritional Sciences | 1 | 1990 | 2 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2009 | 96 | 0.090 |
Why?
| | Sleep Initiation and Maintenance Disorders | 2 | 2012 | 8 | 0.090 |
Why?
| | Patch Tests | 1 | 2010 | 2 | 0.090 |
Why?
| | Single-Blind Method | 1 | 2010 | 14 | 0.090 |
Why?
| | ROC Curve | 1 | 2010 | 21 | 0.090 |
Why?
| | Odds Ratio | 1 | 2010 | 51 | 0.090 |
Why?
| | Immunoglobulin G | 1 | 2010 | 34 | 0.090 |
Why?
| | Health Education | 1 | 1990 | 27 | 0.090 |
Why?
| | Feasibility Studies | 2 | 2020 | 59 | 0.090 |
Why?
| | North America | 1 | 2010 | 43 | 0.090 |
Why?
| | Terminology as Topic | 1 | 2010 | 15 | 0.090 |
Why?
| | Data Collection | 1 | 2010 | 29 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2010 | 43 | 0.090 |
Why?
| | Accelerometry | 2 | 2019 | 46 | 0.090 |
Why?
| | Dietary Fats | 1 | 1989 | 5 | 0.090 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 1989 | 9 | 0.080 |
Why?
| | Gallbladder Diseases | 1 | 1989 | 13 | 0.080 |
Why?
| | Predictive Value of Tests | 3 | 1995 | 102 | 0.080 |
Why?
| | Mice, Inbred C57BL | 2 | 2019 | 90 | 0.080 |
Why?
| | Mechanotransduction, Cellular | 1 | 2008 | 5 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2019 | 198 | 0.080 |
Why?
| | Parents | 2 | 2008 | 152 | 0.080 |
Why?
| | Fasting | 1 | 2006 | 4 | 0.070 |
Why?
| | Young Adult | 2 | 2019 | 641 | 0.070 |
Why?
| | Gallbladder | 1 | 2006 | 3 | 0.070 |
Why?
| | Reference Values | 1 | 2006 | 43 | 0.070 |
Why?
| | Biliary Dyskinesia | 1 | 2006 | 8 | 0.070 |
Why?
| | Hydroxyzine | 1 | 2006 | 1 | 0.070 |
Why?
| | Ranitidine | 1 | 2006 | 5 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2006 | 37 | 0.070 |
Why?
| | Psychology | 1 | 2006 | 4 | 0.070 |
Why?
| | Education, Medical, Continuing | 1 | 2006 | 6 | 0.070 |
Why?
| | China | 2 | 2015 | 10 | 0.070 |
Why?
| | Missouri | 1 | 2006 | 77 | 0.070 |
Why?
| | Endoscopy, Gastrointestinal | 2 | 2015 | 18 | 0.060 |
Why?
| | Risk Assessment | 1 | 2006 | 136 | 0.060 |
Why?
| | Enteritis | 1 | 2024 | 4 | 0.060 |
Why?
| | Infusions, Parenteral | 1 | 2004 | 5 | 0.060 |
Why?
| | Safety | 1 | 2004 | 14 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2024 | 15 | 0.060 |
Why?
| | Histamine H1 Antagonists | 1 | 2024 | 5 | 0.060 |
Why?
| | Clavicle | 1 | 2004 | 1 | 0.060 |
Why?
| | Osteomyelitis | 1 | 2004 | 8 | 0.060 |
Why?
| | Transcriptome | 1 | 2024 | 59 | 0.060 |
Why?
| | Gene Expression Profiling | 1 | 2024 | 125 | 0.060 |
Why?
| | Genomics | 1 | 2024 | 102 | 0.060 |
Why?
| | Factor Analysis, Statistical | 2 | 2013 | 22 | 0.060 |
Why?
| | Posture | 2 | 1994 | 9 | 0.060 |
Why?
| | Psychometrics | 2 | 2013 | 30 | 0.050 |
Why?
| | Administration, Oral | 2 | 2012 | 58 | 0.050 |
Why?
| | Microscopy, Electron | 1 | 2002 | 6 | 0.050 |
Why?
| | Phobic Disorders | 1 | 2022 | 4 | 0.050 |
Why?
| | Disability Evaluation | 1 | 2022 | 14 | 0.050 |
Why?
| | Aspartate Aminotransferases | 1 | 2022 | 4 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2022 | 10 | 0.050 |
Why?
| | Chi-Square Distribution | 2 | 2012 | 35 | 0.050 |
Why?
| | Effect Modifier, Epidemiologic | 1 | 2021 | 2 | 0.050 |
Why?
| | Individuality | 1 | 2021 | 3 | 0.050 |
Why?
| | Body Mass Index | 1 | 2022 | 156 | 0.050 |
Why?
| | Liver | 1 | 2022 | 130 | 0.050 |
Why?
| | Interdisciplinary Communication | 1 | 2019 | 9 | 0.040 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2019 | 7 | 0.040 |
Why?
| | Age Distribution | 1 | 2019 | 32 | 0.040 |
Why?
| | Acute Disease | 1 | 2019 | 77 | 0.040 |
Why?
| | Databases as Topic | 1 | 2019 | 2 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2019 | 32 | 0.040 |
Why?
| | Prenatal Care | 1 | 1999 | 3 | 0.040 |
Why?
| | Interviews as Topic | 1 | 1999 | 20 | 0.040 |
Why?
| | Maternal-Child Nursing | 1 | 1998 | 1 | 0.040 |
Why?
| | Employment | 1 | 1998 | 4 | 0.040 |
Why?
| | Infant Food | 1 | 1998 | 6 | 0.040 |
Why?
| | Mother-Child Relations | 1 | 1998 | 5 | 0.040 |
Why?
| | Patient Discharge | 1 | 2019 | 61 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 98 | 0.040 |
Why?
| | Milk, Human | 1 | 1998 | 24 | 0.040 |
Why?
| | Drug Dosage Calculations | 1 | 2018 | 16 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 1999 | 53 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 103 | 0.040 |
Why?
| | Radiography, Panoramic | 1 | 2018 | 3 | 0.040 |
Why?
| | Jaw | 1 | 2018 | 3 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2018 | 15 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2018 | 68 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2018 | 60 | 0.040 |
Why?
| | Signal Transduction | 1 | 2019 | 133 | 0.040 |
Why?
| | Length of Stay | 1 | 2019 | 243 | 0.040 |
Why?
| | Pregnancy | 1 | 1999 | 212 | 0.040 |
Why?
| | Stomatitis | 1 | 1997 | 1 | 0.040 |
Why?
| | Oral Ulcer | 1 | 1997 | 1 | 0.040 |
Why?
| | Genotype | 1 | 2018 | 408 | 0.040 |
Why?
| | Mice | 1 | 2018 | 339 | 0.040 |
Why?
| | Mutation | 1 | 2018 | 213 | 0.040 |
Why?
| | Recurrence | 2 | 2008 | 121 | 0.040 |
Why?
| | Down-Regulation | 1 | 2016 | 14 | 0.030 |
Why?
| | Microfilament Proteins | 1 | 2016 | 12 | 0.030 |
Why?
| | Parenteral Nutrition, Total | 1 | 1996 | 7 | 0.030 |
Why?
| | Hypoalbuminemia | 1 | 2015 | 4 | 0.030 |
Why?
| | Milk | 1 | 2015 | 6 | 0.030 |
Why?
| | Cattle | 1 | 2015 | 24 | 0.030 |
Why?
| | Failure to Thrive | 1 | 2015 | 7 | 0.030 |
Why?
| | Syndrome | 1 | 2015 | 34 | 0.030 |
Why?
| | Malnutrition | 1 | 2015 | 8 | 0.030 |
Why?
| | Physical Therapy Modalities | 1 | 1995 | 4 | 0.030 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2016 | 47 | 0.030 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2015 | 16 | 0.030 |
Why?
| | Bronchodilator Agents | 1 | 1995 | 11 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2015 | 47 | 0.030 |
Why?
| | Fluid Therapy | 1 | 1995 | 19 | 0.030 |
Why?
| | Neoplasms | 1 | 1998 | 126 | 0.030 |
Why?
| | Hypoglycemia | 1 | 1996 | 31 | 0.030 |
Why?
| | Sodium Acetate | 1 | 2015 | 2 | 0.030 |
Why?
| | Carbon Isotopes | 1 | 2015 | 4 | 0.030 |
Why?
| | Regression Analysis | 1 | 1995 | 52 | 0.030 |
Why?
| | Wakefulness | 1 | 1994 | 2 | 0.030 |
Why?
| | Blood Gas Analysis | 1 | 1994 | 7 | 0.030 |
Why?
| | Causality | 1 | 1994 | 10 | 0.030 |
Why?
| | Proxy | 1 | 2013 | 2 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2013 | 14 | 0.030 |
Why?
| | Interpersonal Relations | 1 | 2012 | 11 | 0.030 |
Why?
| | Social Participation | 1 | 2012 | 2 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 1995 | 243 | 0.030 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2012 | 12 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2012 | 38 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 1992 | 8 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2012 | 63 | 0.030 |
Why?
| | Molasses | 1 | 2012 | 2 | 0.030 |
Why?
| | Osmosis | 1 | 2012 | 2 | 0.030 |
Why?
| | Schools | 1 | 2012 | 56 | 0.030 |
Why?
| | Feces | 1 | 2012 | 38 | 0.030 |
Why?
| | Diagnosis, Differential | 2 | 2005 | 78 | 0.030 |
Why?
| | Patient Readmission | 1 | 2012 | 70 | 0.020 |
Why?
| | Erythroblastosis, Fetal | 1 | 1989 | 2 | 0.020 |
Why?
| | Jaundice | 1 | 1989 | 4 | 0.020 |
Why?
| | Abdomen | 1 | 1989 | 14 | 0.020 |
Why?
| | Self Disclosure | 1 | 2008 | 4 | 0.020 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 1989 | 40 | 0.020 |
Why?
| | Social Behavior | 1 | 2008 | 11 | 0.020 |
Why?
| | Emotions | 1 | 2008 | 21 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2008 | 43 | 0.020 |
Why?
| | Child Behavior | 1 | 2008 | 29 | 0.020 |
Why?
| | Heart Defects, Congenital | 1 | 1989 | 81 | 0.020 |
Why?
| | Diagnostic Techniques, Digestive System | 1 | 2007 | 5 | 0.020 |
Why?
| | Anthropometry | 1 | 2007 | 16 | 0.020 |
Why?
| | Tryptases | 1 | 2006 | 1 | 0.020 |
Why?
| | Cholecystectomy | 1 | 2006 | 8 | 0.020 |
Why?
| | Serine Endopeptidases | 1 | 2006 | 5 | 0.020 |
Why?
| | Hypnotics and Sedatives | 1 | 2005 | 6 | 0.020 |
Why?
| | Indiana | 1 | 1998 | 2 | 0.010 |
Why?
| | Cysteine Endopeptidases | 1 | 1998 | 2 | 0.010 |
Why?
| | Fluorescence | 1 | 1998 | 7 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1998 | 26 | 0.010 |
Why?
| | Clobetasol | 1 | 1997 | 1 | 0.010 |
Why?
| | Sarcoidosis | 1 | 1997 | 1 | 0.010 |
Why?
| | Administration, Topical | 1 | 1997 | 6 | 0.010 |
Why?
| | Glucocorticoids | 1 | 1997 | 31 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 34 | 0.010 |
Why?
| | Insulin | 1 | 1996 | 49 | 0.010 |
Why?
| | Blood Glucose | 1 | 1996 | 59 | 0.010 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|